Ann Dornfeld, a reporter at KUOW (a local affiliate of NPR), featured Dr. Ho in an article titled “False advertising: This Seattle doctor set up a dubious Covid testing site in a vacant hotel.” In the article, Dr. Ho discusses the issues with FDA oversight of new COVID-19 tests and the problem of false claims test manufacturers can make during the pandemic. For the whole story, follow the link.
News
The Healthy Talks Antibody Testing with Dr. Ho
The Healthy, an imprint of Reader’s Digest covering health has posted an Amanda Gardner article featuring Dr. Ho. Here, Dr. Ho discusses the role of antibody testing in COVID-19. The article, titled “Coronavirus Testing: Everything You Need to Know”can be found at the link.
Knowable Magazine Features Dr. Ho in COVID-19 Newsletter
Knowable Magazine featured Dr. Ho in a discussion on the possible links between the use of non-steroidal anti-inflammatory drugs (NSAIDS) and worsened COVID-19 symptoms. For the whole piece, follow the link.
KOMO News 4 Interviews Dr. Ho on COVID-19
Watch Dr. Ho explain how antivirals might only be effective for early stage treatment of COVID-19. KOMO News 4 of Seattle covered the story. For the full talk, follow the link.
USA Today Covers Coronavirus with Dr. Ho
Dr. Ho discussed some of the complications of treating COVID-19 with vaccines and therapeutics with USA Today in an article by Elizabeth Wise titled “Scientists chase two fronts in how to treat coronavirus, but ‘there’s no magic drug right now.'” For the whole story, follow the link.
Salon Interviews Dr. Ho on Chloroquine
Salon’s Nicole Karlis interviewed Dr. Ho about the history of chloroquine and hyroxychloroquine, what role they could play in treating COVID-19, and the possible side effects. For the whole interview follow the link.
Dr. Ho explains Antimalarial Hydroxychloroquine and COVID-19 with Geekwire
Dr. Ho contributed to an article by Geekwire’s Karina Mazhukhina on hydroxychloroquine as a potential treatment for COVID-19. For the whole story, titled “UW treating COVID-19 patients with antimalarial drug—researcher calls it ‘very promising,'” follow the link.
TLC-ART’s Dr. Perazzolo Discusses Covid-19 Treatment on Italian National TV
Dr. Simone Perazzolo, a scientist in the TLC-ART Program, was featured on Italian national TV explaining how an FDA approved protease inhibitor called Lopinavir (Kaletra) may be effective against Covid-19 since requires protease enzymes to replicate.
TLC-ART GLAD Project Covered at LAII 2020
The 3rd Long-Acting Injectables and Implantables Conference (LAII 2020) in La Jolla yesterday and today is covering cutting edge developments in pharmaceutics, including TLC-ART’s newly funded Global Long-Acting Drug (GLAD) Project, transforming daily oral tenofovir-lamivudine-dolutegravir (TLD) pills into a long-acting injectable product for global access.
Unitaid Announces $6.9 Million Funding for TLC-ART to Transform Current HIV Drugs into Long-Acting Injectables for Worldwide Use
Unitaid, a hosted funding partner of the WHO, announced investment in the TLC-ART drug-combination nanoparticle platform technology to transform current short-acting HIV drug combinations into long-acting medicines to simplify treatment for people living with HIV.